Dietary Supplement Regulation: What the 2026 Listing Bill Would—and Would Not—Change

Most Americans buying a dietary supplement assume someone, somewhere, checked whether it works. Under federal law, nobody did.

Dietary supplements are regulated more like foods than drugs. The Food and Drug Administration does not approve them, and manufacturers are not required to demonstrate effectiveness before marketing. The agency states that it is generally limited to postmarket enforcement because, unlike drugs that must be proven safe and effective before sale, no provision in the law allows FDA to approve supplements for safety before they reach consumers.

That framework has been in place since 1994, while the market it governs has expanded enormously. More than 75 percent of American adults now use a dietary supplement, and annual sales have grown from about $4 billion to more than $50 billion over three decades.

The Regulatory Framework Most Buyers Assume Is Stricter

The Dietary Supplement Health and Education Act of 1994 (DSHEA) created supplements as a distinct product category and placed the compliance burden primarily on manufacturers, who are responsible for ensuring their products are safe and accurately labeled before marketing.

What the FDA does regulate is real but narrower than most people expect. The agency sets and inspects against current good manufacturing practice requirements, reviews new dietary ingredient notifications, monitors imports, investigates adverse event reports, and can act against products that are adulterated or misbranded once they are on the market. Certain claims, such as authorized health claims, do require premarket review.

Structure and function claims—the familiar language about supporting immunity or promoting joint comfort—do not require FDA authorization. They require only that the manufacturer notify the agency and carry a disclaimer. The agency has separately signaled it is weighing a regulatory amendment to the requirements around that disclaimer.

Advertising falls to the Federal Trade Commission, which requires that claims be substantiated by competent and reliable evidence. FTC scrutiny of weight loss and cognitive claims has continued through 2026, alongside attention to performance benefit claims, influencer marketing, and broad natural positioning.

Enforcement Capacity Against a Very Large Market

The scale problem is arithmetic. Estimates of how many products are on the market range from about 80,000 to more than 100,000, against roughly 4,000 when the 1994 law passed. More than 1,000 new dietary supplements enter the market every year. Because there is no registry, the agency does not have a comprehensive list of what is being sold. That limitation surfaces most visibly during safety events, when regulators cannot quickly identify which products contain an ingredient of concern.

The adverse event data illustrate the gap between what is reported and what happens. FDA received more than 2,000 adverse event reports in one year related to dietary supplements in 2023, but the agency has estimated that significant underreporting means the true annual figure exceeds 50,000.

Organizational changes are underway. The Office of Dietary Supplement Programs now sits within a newly established Office of Food Chemical Safety, Dietary Supplements and Innovation, and the agency's Human Foods Program has published 2026 priorities emphasizing risk-based enforcement and modernization.

The Listing Bill and What It Would Not Do

Legislation has been introduced that would require manufacturers to list their products with FDA, and understanding its limits matters as much as its contents.

The Dietary Supplement Listing Act of 2026, introduced by Sen. Dick Durbin of Illinois, would create a mandatory product registry. Companies would have to provide product names, a full ingredient list, an electronic copy of the label, allergen statements, and any health or structure and function claims, with the information published in a searchable public database. Proprietary blend details would go to FDA but stay confidential, and failure to comply would render a product misbranded.

Critically, the bill preserves the existing statutory framework and does not authorize FDA to require premarket approval of supplements. This is Durbin's third attempt after versions in 2022 and 2024 failed, and his final push before he retires in January 2027. The bill has not become law.

Industry is divided. The Council for Responsible Nutrition (搜索)搜索该词条, which endorsed the bill alongside the Consumer Federation of America, U.S. Pharmacopeia (搜索)搜索该词条, and U.S. PIRG, argues a registry would give FDA visibility, target bad actors, and build consumer trust. The Natural Products Association (搜索)搜索该词条 opposes it, characterizing mandatory listing as federal overreach that would undermine the 1994 law, and arguing FDA already has ample means to review labels and should focus on removing unlawful products instead.

Even if enacted, a listing requirement would tell regulators what exists. It would not establish that anything works.

Marketing Tactics That Create False Confidence

David Trosin, Senior Director of Nutrition and Wellness at NSF, has highlighted two misleading tactics that appear on supplement bottles repeatedly.

"One of the things that drives me nuts is, they'll say 'FDA registered,'" Trosin said during a roundtable discussion. "What that means is, congratulations, you can go online and fill out a form." The designation only indicates that a company has filed basic information with the FDA—not that the agency has reviewed, tested, or verified the safety, efficacy, or quality of the supplement.

"It makes me so angry when I see that, because to a consumer who doesn't know what that means, they're thinking that the supplement company has gone through the extra steps. That the FDA has evaluated or somehow approved of what they do," Trosin said.

Similarly, phrases like "independently tested" or "third-party certified" are not regulated. Any brand can print them on its packaging, even if no outside lab ever tested the product. "All that took was Photoshop, really," Trosin said. "There's no grit behind it to indicate that it means something."

In some cases, bad actors turn to so-called "dry labs"—companies that produce testing reports without actually verifying the supplements. "If you sent me your product and I was running a dry lab, basically, I would just have an office building or a PO box," Trosin explained. "I have no equipment. I'm not actually testing the product. I'm just writing a test report and sending it back to them, and that costs $395."

Evidence-Based Uses and Practical Guidance

None of this means supplements are useless or that anyone should stop a product a clinician recommended. Vitamin D for documented deficiency, folic acid in pregnancy, B12 for certain conditions, and iron for diagnosed anemia are evidence-based uses.

The practical step for shoppers is checking for third-party verification. Programs run by organizations such as USP, NSF International (搜索)搜索该词条, and ConsumerLab (搜索)搜索该词条 test whether a product contains what its label claims and is free of specified contaminants. That verification addresses identity and purity, not whether the ingredient produces a health benefit. For NSF-certified supplements, consumers can look for the organization's circular NSF logo on the packaging and verify certified products and batch numbers through NSF's official online database.

Claims themselves are a useful filter. A product promising to cure, treat, or prevent a disease is making a drug claim, which is not permitted for a supplement and signals a seller operating outside the rules. Language about supporting or promoting a function is legal but carries no evidentiary requirement.

Anyone taking prescription medication should tell their pharmacist and prescriber about every supplement they use. Interactions are common and consequential, including with blood thinners, thyroid medication, antidepressants, transplant medications, and chemotherapy. People who are pregnant, breastfeeding, managing liver or kidney disease, or preparing for surgery should ask before starting anything new.

Suspected harm from a supplement can be reported to FDA through the MedWatch program, and reports feed the adverse event system the agency relies on for postmarket signals. Symptoms that warrant prompt medical attention after starting a supplement include yellowing of the eyes or skin, dark urine, severe abdominal pain, chest pain, irregular heartbeat, or a rash with swelling or difficulty breathing.

The bottom line: supplements reach shelves without any federal demonstration of effectiveness. FDA regulates manufacturing, labeling, and safety through postmarket enforcement across a market estimated at 80,000 to more than 100,000 products. A listing bill remains pending and would not add effectiveness review. The most useful consumer steps are checking third-party verification and telling a pharmacist what you take.